LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01523587
First received: January 30, 2012
Last updated: August 6, 2014
Last verified: August 2014
  Purpose

This randomised, open-label phase III trial will be performed in patients with advanced squamous cell carcinoma of the lung requiring second-line treatment after receiving first-line platinum-based chemotherapy. The primary objective of this trial is to compare the efficacy of BIBW 2992 to erlotinib as second-line treatment in this group of patients.


Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung
Drug: afatinib
Drug: erlotinib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Progression-free survival, as determined by RECIST 1.1 [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 795
Study Start Date: March 2012
Estimated Study Completion Date: November 2015
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Afatinib
Patients receive afatinib tablets once daily
Drug: afatinib
Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
Active Comparator: Erlotinib
Patients receive erlotinib tablets once daily
Drug: erlotinib
erlotinib taken once daily

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Diagnosis of advanced stage NSCLC squamous histology.
  2. Platinum-based doublet chemotherapy as 1st line treatment of Stage IIIB/IV NSCLC.
  3. Eligible to receive 2nd line therapy in the opinion of the investigator.
  4. Measurable disease according to RECIST 1.1.
  5. Adequate Performance Status.
  6. Availability of tumour tissue material for correlative studies. Archived tumour tissue is acceptable.
  7. Adequate organ function.
  8. Age = 18 years and above.
  9. Written informed consent that is consistent with ICH-GCP guidelines.

Exclusion criteria:

  1. Prior treatment with EGFR directed small molecules or antibodies.
  2. Radiotherapy within 4 weeks prior to randomization.
  3. Active brain metastases .
  4. Any other current malignancy or malignancy diagnosed within the past three (3) years (other than basal-cell carcinoma of the skin, in situ cervical cancer, in situ prostate cancer).
  5. Known pre-existing interstitial lung disease.
  6. Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom
  7. Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test drug.
  8. Women of child-bearing potential and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 2 months after treatment has ended.
  9. Female patients of childbearing potential (see Section 4.2.3.3) who:

    1. are nursing or
    2. are pregnant or
    3. are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.
  10. Active hepatitis B infection (defined as presence of Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.
  11. Known or suspected active drug or alcohol abuse in the opinion of the investigator.
  12. Any contraindications for therapy with afatinib or erlotinib.
  13. Known hypersensitivity to erlotinib, afatinib or the excipients of any of the trial drugs.
  14. Major surgery within 4 weeks of starting study treatment.
  15. Prior participation in an afatinib clinical study, even if not assigned to afatinib.
  16. Use of any investigational drug within 4 weeks of randomisation (unless a longer time period is required by local regulations or by the guidelines for the investigational product).
  17. Patients without Progression of their lung cancer.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01523587

  Hide Study Locations
Locations
United States, Arizona
1200.125.10073 Boehringer Ingelheim Investigational Site
Chandler, Arizona, United States
United States, California
1200.125.10041 Boehringer Ingelheim Investigational Site
La Jolla, California, United States
1200.125.10019 Boehringer Ingelheim Investigational Site
Sacramento, California, United States
United States, Florida
1200.125.10067 Boehringer Ingelheim Investigational Site
Boca Raton, Florida, United States
1200.125.10066 Boehringer Ingelheim Investigational Site
Hollywood, Florida, United States
1200.125.10009 Boehringer Ingelheim Investigational Site
Lake City, Florida, United States
United States, Illinois
1200.125.10064 Boehringer Ingelheim Investigational Site
Niles, Illinois, United States
1200.125.10011 Boehringer Ingelheim Investigational Site
Skokie, Illinois, United States
United States, Kentucky
1200.125.10032 Boehringer Ingelheim Investigational Site
Louisville, Kentucky, United States
United States, Louisiana
1200.125.10083 Boehringer Ingelheim Investigational Site
Marrero, Louisiana, United States
United States, Massachusetts
1200.125.10048 Boehringer Ingelheim Investigational Site
Burlington, Massachusetts, United States
1200.125.10072 Boehringer Ingelheim Investigational Site
Lawrence, Massachusetts, United States
United States, Michigan
1200.125.10028 Boehringer Ingelheim Investigational Site
Detroit, Michigan, United States
United States, Missouri
1200.125.10057 Boehringer Ingelheim Investigational Site
St. Louis, Missouri, United States
United States, Montana
1200.125.10077 Boehringer Ingelheim Investigational Site
Billings, Montana, United States
United States, New York
1200.125.10088 Boehringer Ingelheim Investigational Site
Bronx, New York, United States
1200.125.10069 Boehringer Ingelheim Investigational Site
Bronx, New York, United States
1200.125.10015 Boehringer Ingelheim Investigational Site
Fresh Meadows, New York, United States
1200.125.10062 Boehringer Ingelheim Investigational Site
Syracuse, New York, United States
United States, Ohio
1200.125.10024 Boehringer Ingelheim Investigational Site
Cleveland, Ohio, United States
1200.125.10070 Boehringer Ingelheim Investigational Site
Columbus, Ohio, United States
1200.125.10050 Boehringer Ingelheim Investigational Site
Columbus, Ohio, United States
United States, Oregon
1200.125.10040 Boehringer Ingelheim Investigational Site
Portland, Oregon, United States
United States, Pennsylvania
1200.125.10063 Boehringer Ingelheim Investigational Site
DuBois, Pennsylvania, United States
1200.125.10079 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
1200.125.10078 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
United States, South Carolina
1200.125.10016 Boehringer Ingelheim Investigational Site
Spartanburg, South Carolina, United States
United States, Tennessee
1200.125.10068 Boehringer Ingelheim Investigational Site
Cookeville, Tennessee, United States
United States, Texas
1200.125.10055 Boehringer Ingelheim Investigational Site
Paris, Texas, United States
1200.125.10022 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
United States, Vermont
1200.125.10061 Boehringer Ingelheim Investigational Site
Burlington, Vermont, United States
United States, Virginia
1200.125.10051 Boehringer Ingelheim Investigational Site
Christianburg, Virginia, United States
1200.125.10074 Boehringer Ingelheim Investigational Site
Norfolk, Virginia, United States
Argentina
1200.125.54004 Boehringer Ingelheim Investigational Site
Ciudad Autonoma de Buenos Aires, Argentina
1200.125.54006 Boehringer Ingelheim Investigational Site
Cordoba, Argentina
1200.125.54008 Boehringer Ingelheim Investigational Site
Cordoba, Argentina
1200.125.54002 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1200.125.54007 Boehringer Ingelheim Investigational Site
San Miguel de Tucuman, Argentina
Austria
1200.125.43004 Boehringer Ingelheim Investigational Site
Innsbruck, Austria
1200.125.43008 Boehringer Ingelheim Investigational Site
Leoben, Austria
1200.125.43010 Boehringer Ingelheim Investigational Site
Linz, Austria
1200.125.43007 Boehringer Ingelheim Investigational Site
Wien, Austria
1200.125.43001 Boehringer Ingelheim Investigational Site
Wien, Austria
Canada, British Columbia
1200.125.11004 Boehringer Ingelheim Investigational Site
Surrey, British Columbia, Canada
Canada, Ontario
1200.125.11002 Boehringer Ingelheim Investigational Site
Kingston, Ontario, Canada
1200.125.11001 Boehringer Ingelheim Investigational Site
Ottawa, Ontario, Canada
Canada, Quebec
1200.125.11007 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1200.125.11003 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
Chile
1200.125.56006 Boehringer Ingelheim Investigational Site
Antofagasta, Chile
1200.125.56002 Boehringer Ingelheim Investigational Site
Providencia, Santiago, Chile
1200.125.56001 Boehringer Ingelheim Investigational Site
Recoleta, Santiago de Chile, Chile
1200.125.56003 Boehringer Ingelheim Investigational Site
Vitacura, Chile
China
1200.125.86007 Boehringer Ingelheim Investigational Site
Beijing, China
1200.125.86003 Boehringer Ingelheim Investigational Site
Beijing, China
1200.125.86004 Boehringer Ingelheim Investigational Site
Changchun, China
1200.125.86006 Boehringer Ingelheim Investigational Site
Changsha, China
1200.125.86005 Boehringer Ingelheim Investigational Site
Guangzhou, China
1200.125.86002 Boehringer Ingelheim Investigational Site
Nanjing, China
1200.125.86009 Boehringer Ingelheim Investigational Site
Nanjing, China
1200.125.86008 Boehringer Ingelheim Investigational Site
Shanghai, China
1200.125.86001 Boehringer Ingelheim Investigational Site
Shanghai, China
Denmark
1200.125.45002 Boehringer Ingelheim Investigational Site
Herlev, Denmark
1200.125.45003 Boehringer Ingelheim Investigational Site
Næstved, Denmark
1200.125.45001 Boehringer Ingelheim Investigational Site
Odense C, Denmark
France
1200.125.33029 Boehringer Ingelheim Investigational Site
Angers Cedex 9, France
1200.125.33020 Boehringer Ingelheim Investigational Site
Bordeaux, France
1200.125.33001 Boehringer Ingelheim Investigational Site
Caen, France
1200.125.33022 Boehringer Ingelheim Investigational Site
Chauny, France
1200.125.33023 Boehringer Ingelheim Investigational Site
Clermont Ferrand, France
1200.125.33007 Boehringer Ingelheim Investigational Site
Creteil, France
1200.125.33016 Boehringer Ingelheim Investigational Site
Le Mans, France
1200.125.33005 Boehringer Ingelheim Investigational Site
Lille, France
1200.125.33015 Boehringer Ingelheim Investigational Site
Lille, France
1200.125.33012 Boehringer Ingelheim Investigational Site
Marseille, France
1200.125.33003 Boehringer Ingelheim Investigational Site
Marseille Cedex 20, France
1200.125.33010 Boehringer Ingelheim Investigational Site
Mulhouse, France
1200.125.33011 Boehringer Ingelheim Investigational Site
Paris, France
1200.125.33006 Boehringer Ingelheim Investigational Site
Paris, France
1200.125.33018 Boehringer Ingelheim Investigational Site
Reims, France
1200.125.33019 Boehringer Ingelheim Investigational Site
Rennes, France
1200.125.33027 Boehringer Ingelheim Investigational Site
Saint Quentin, France
1200.125.33028 Boehringer Ingelheim Investigational Site
Strasbourg, France
1200.125.33026 Boehringer Ingelheim Investigational Site
Suresnes, France
1200.125.33002 Boehringer Ingelheim Investigational Site
Villejuif, France
Germany
1200.125.49005 Boehringer Ingelheim Investigational Site
Bad Berka, Germany
1200.125.49002 Boehringer Ingelheim Investigational Site
Essen, Germany
1200.125.49009 Boehringer Ingelheim Investigational Site
Esslingen, Germany
1200.125.49011 Boehringer Ingelheim Investigational Site
Frankfurt am Main, Germany
1200.125.49001 Boehringer Ingelheim Investigational Site
Freiburg, Germany
1200.125.49008 Boehringer Ingelheim Investigational Site
Hamburg, Germany
1200.125.49007 Boehringer Ingelheim Investigational Site
Hemer, Germany
1200.125.49003 Boehringer Ingelheim Investigational Site
Mannheim, Germany
1200.125.49010 Boehringer Ingelheim Investigational Site
Münster, Germany
1200.125.49006 Boehringer Ingelheim Investigational Site
Rheine, Germany
Greece
1200.125.30003 Boehringer Ingelheim Investigational Site
Athens, Greece
1200.125.30009 Boehringer Ingelheim Investigational Site
Athens, Greece
1200.125.30001 Boehringer Ingelheim Investigational Site
Heraklion, Greece
1200.125.30007 Boehringer Ingelheim Investigational Site
Larisa, Greece
1200.125.30005 Boehringer Ingelheim Investigational Site
Larisa, Greece
1200.125.30008 Boehringer Ingelheim Investigational Site
Neo Faliro, Athens, Greece
1200.125.30002 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
Hungary
1200.125.36005 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1200.125.36002 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1200.125.36001 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1200.125.36003 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1200.125.36006 Boehringer Ingelheim Investigational Site
Deszk, Hungary
1200.125.36009 Boehringer Ingelheim Investigational Site
Farkasgyepü, Hungary
1200.125.36010 Boehringer Ingelheim Investigational Site
Györ, Hungary
1200.125.36011 Boehringer Ingelheim Investigational Site
Matrahaza, Hungary
1200.125.36007 Boehringer Ingelheim Investigational Site
Nyiregyhaza, Hungary
1200.125.36008 Boehringer Ingelheim Investigational Site
Pecs, Hungary
1200.125.36004 Boehringer Ingelheim Investigational Site
Törökbalint, Hungary
India
1200.125.91007 Boehringer Ingelheim Investigational Site
Bangalore, India
1200.125.91009 Boehringer Ingelheim Investigational Site
Chennai, India
1200.125.91002 Boehringer Ingelheim Investigational Site
Chennai, India
1200.125.91001 Boehringer Ingelheim Investigational Site
Chennai, India
1200.125.91008 Boehringer Ingelheim Investigational Site
Coimbatore, India
1200.125.91004 Boehringer Ingelheim Investigational Site
Karamsad, India
1200.125.91005 Boehringer Ingelheim Investigational Site
Kolkata, West Bengal, India
1200.125.91012 Boehringer Ingelheim Investigational Site
Mumbai, India
1200.125.91014 Boehringer Ingelheim Investigational Site
Pune, India
Ireland
1200.125.35301 Boehringer Ingelheim Investigational Site
Dublin 8, Ireland
Italy
1200.125.39002 Boehringer Ingelheim Investigational Site
Bologna, Italy
1200.125.39008 Boehringer Ingelheim Investigational Site
Cremona, Italy
1200.125.39011 Boehringer Ingelheim Investigational Site
Livorno, Italy
1200.125.39007 Boehringer Ingelheim Investigational Site
Napoli, Italy
1200.125.39005 Boehringer Ingelheim Investigational Site
Padova, Italy
1200.125.39001 Boehringer Ingelheim Investigational Site
Parma, Italy
1200.125.39004 Boehringer Ingelheim Investigational Site
Pisa, Italy
1200.125.39009 Boehringer Ingelheim Investigational Site
Rozzano (MI), Italy
1200.125.39006 Boehringer Ingelheim Investigational Site
Taormina, Italy
1200.125.39003 Boehringer Ingelheim Investigational Site
Torino, Italy
1200.125.39010 Boehringer Ingelheim Investigational Site
Udine, Italy
Korea, Republic of
1200.125.82001 Boehringer Ingelheim Investigational Site
Cheongju, Korea, Republic of
1200.125.82004 Boehringer Ingelheim Investigational Site
Gyeonggi-Do, Korea, Republic of
1200.125.82002 Boehringer Ingelheim Investigational Site
Incheon, Korea, Republic of
1200.125.82010 Boehringer Ingelheim Investigational Site
Jinju, Korea, Republic of
1200.125.82004 Boehringer Ingelheim Investigational Site
Seongnam, Korea, Republic of
1200.125.82006 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1200.125.82003 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1200.125.82005 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1200.125.82008 Boehringer Ingelheim Investigational Site
Suwon, Korea, Republic of
1200.125.82007 Boehringer Ingelheim Investigational Site
Ulsan, Korea, Republic of
Mexico
1200.125.52001 Boehringer Ingelheim Investigational Site
Mexico, Mexico
1200.125.52003 Boehringer Ingelheim Investigational Site
Monterrey, Mexico
1200.125.52002 Boehringer Ingelheim Investigational Site
Toluca, Mexico
Netherlands
1200.125.31009 Boehringer Ingelheim Investigational Site
Arnhem, Netherlands
1200.125.31001 Boehringer Ingelheim Investigational Site
Breda, Netherlands
1200.125.31002 Boehringer Ingelheim Investigational Site
Den Bosch, Netherlands
1200.125.31003 Boehringer Ingelheim Investigational Site
Eindhoven, Netherlands
1200.125.31004 Boehringer Ingelheim Investigational Site
Maastricht, Netherlands
1200.125.31006 Boehringer Ingelheim Investigational Site
Nieuwegein, Netherlands
1200.125.31007 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
Portugal
1200.125.12002 Boehringer Ingelheim Investigational Site
Porto, Portugal
Singapore
1200.125.65002 Boehringer Ingelheim Investigational Site
Singapore, Singapore
1200.125.65001 Boehringer Ingelheim Investigational Site
Singapore, Singapore
Spain
1200.125.34010 Boehringer Ingelheim Investigational Site
A Coruña, Spain
1200.125.34008 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1200.125.34001 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1200.125.34006 Boehringer Ingelheim Investigational Site
Madrid, Spain
1200.125.34003 Boehringer Ingelheim Investigational Site
Madrid, Spain
1200.125.34007 Boehringer Ingelheim Investigational Site
Malaga, Spain
1200.125.34004 Boehringer Ingelheim Investigational Site
Malaga, Spain
1200.125.34005 Boehringer Ingelheim Investigational Site
Valencia, Spain
1200.125.34002 Boehringer Ingelheim Investigational Site
Zaragoza, Spain
Taiwan
1200.125.88006 Boehringer Ingelheim Investigational Site
Chiayi, Taiwan
1200.125.88009 Boehringer Ingelheim Investigational Site
Chiayi, Taiwan
1200.125.88007 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
1200.125.88005 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1200.125.88004 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1200.125.88002 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1200.125.88001 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1200.125.88008 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1200.125.88003 Boehringer Ingelheim Investigational Site
Taoyuan, Taiwan
Turkey
1200.125.90004 Boehringer Ingelheim Investigational Site
Antalya, Turkey
1200.125.90006 Boehringer Ingelheim Investigational Site
Bursa, Turkey
1200.125.90002 Boehringer Ingelheim Investigational Site
Diyarbakir, Turkey
1200.125.90003 Boehringer Ingelheim Investigational Site
Gaziantep, Turkey
1200.125.90008 Boehringer Ingelheim Investigational Site
Istanbul, Turkey
1200.125.90007 Boehringer Ingelheim Investigational Site
Istanbul, Turkey
1200.125.90009 Boehringer Ingelheim Investigational Site
Izmir, Turkey
1200.125.90001 Boehringer Ingelheim Investigational Site
Izmir, Turkey
United Kingdom
1200.125.44006 Boehringer Ingelheim Investigational Site
Birmingham, United Kingdom
1200.125.44003 Boehringer Ingelheim Investigational Site
Exeter, United Kingdom
1200.125.44008 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
1200.125.44010 Boehringer Ingelheim Investigational Site
Harrogate, United Kingdom
1200.125.44001 Boehringer Ingelheim Investigational Site
London, United Kingdom
1200.125.44004 Boehringer Ingelheim Investigational Site
London, United Kingdom
1200.125.44005 Boehringer Ingelheim Investigational Site
Maidstone, United Kingdom
1200.125.44007 Boehringer Ingelheim Investigational Site
Nottingham, United Kingdom
1200.125.44009 Boehringer Ingelheim Investigational Site
Scarborough, United Kingdom
1200.125.44002 Boehringer Ingelheim Investigational Site
Sutton, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01523587     History of Changes
Other Study ID Numbers: 1200.125, 2011-002380-24
Study First Received: January 30, 2012
Last Updated: August 6, 2014
Health Authority: Argentina: Admin Nacional de Medicamentos, Alimentos Tecnologia Medica
Austria: Medicines and Medical Devices Agency
Canada: Health Canada
Chile: Instituto de Salud Pública de Chile
China: Food and Drug Administration
Denmark: The Danish Health and Medicines Authority
France: Agence Nationale sécurité médicament et des produits santé
Germany: Paul-Ehrlich-Institute
Greece: Ethics Committee
Hungary: National Institute of Pharmacy
India: Drugs Controller General of India
Ireland: Irish Medicines Board
Italy: Ethics Committee
Mexico: Federal Commission for Sanitary Risks Protection
Netherlands: Central Committee Research Involving Human Subjects
Portugal: National Pharmacy and Medicines Institute
Singapore: Health Sciences Authority
South Korea: Ministry of Food and Drug Safety (MFDS)
Spain: Spanish Agency of Medicines
Taiwan : Food and Drug Administration
Turkey: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Non-Small-Cell Lung
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Lung Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Erlotinib
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors

ClinicalTrials.gov processed this record on October 23, 2014